A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension

Trial Profile

A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Tobramycin/prednisolone acetate (Primary) ; Prednisolone acetate
  • Indications Bacterial infections; Ophthalmic infections
  • Focus Pharmacokinetics
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 07 Sep 2012 Company Bausch and Lomb added as an association and lead centre.
    • 07 Sep 2012 Planned number of patients (132) added as reported by ClinicalTrials.gov record.
    • 30 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top